Two renal cancer-related studies by Dr. Kan Gong ‘s team selected for the 2023 EAU Annual Meeting

Two renal cancer-related studies by Dr. Kan Gong ‘s team selected for the 2023 EAU Annual Meeting

2024.01.15
The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world's fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two kidney cancer-related studies from the team of Dr  Kan Gong of Peking University First Hospital were selected for discussion. The research indicates that the age of first onset is an independent risk factor affecting the prognosis in patients with large fragment deletions of Von Hippel-Lindau (VHL) syndrome. These patients may benefit from tyrosine kinase inhibitor (TKI) treatment. Initial CD4+T cells and memory CD4+T cells may be specific immune cells infiltrating VHL syndrome-related kidney cancer, and their infiltration level is closely related to VHL protein expression and patient prognosis.
Two Studies of Dr. Yong Xu’s Team at the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

Two Studies of Dr. Yong Xu’s Team at the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

2024.01.15
The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year's EAU Congress, Dr. Yong Xu's team from the Second Hospital of Tianjin Medical University had two related studies on prostate cancer selected for presentation, exploring radical excision surgery without biopsies for highly suspicious prostate cancer patients and comparing regional saturation biopsies to targeted biopsies for initial evaluation of suspected prostate cancer patients. These research findings offer new perspectives on prostate cancer biopsies and non-invasive diagnostics.
The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference

The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference

2023.10.12
The 38th European Association of Urology (EAU23) Annual Meeting took place from March 10th to 13th, 2023, in Milan, Italy, the fashion capital of the world. The EAU Annual Meeting is one of the most closely watched urological conferences in Europe and even globally, attracting over 15,000 urology experts from around the world each year. At this conference, West China Hospital of Sichuan University reported Several studies.
Two Studies of Dr. Yong Xu’s Teamat the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

Two Studies of Dr. Yong Xu’s Teamat the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

2023.10.12
The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year's EAU Congress, Dr. Yong Xu's team from the Second Hospital of Tianjin Medical University had two related studies on prostate cancer selected for presentation, exploring radical excision surgery without biopsies for highly suspicious prostate cancer patients and comparing regional saturation biopsies to targeted biopsies for initial evaluation of suspected prostate cancer patients. These research findings offer new perspectives on prostate cancer biopsies and non-invasive diagnostics.
Two renal cancer-related studies by Dr. KanGong ‘s team selected for the 2023 EAU Annual Meeting

Two renal cancer-related studies by Dr. KanGong ‘s team selected for the 2023 EAU Annual Meeting

2023.10.12
The 38th European Association of Urology Annual Meeting (EAU23) was held in Milan, Italy, the world's fashion capital, from March 10 to 13, 2023. The EAU annual conference is one of the most closely watched urology conferences in Europe and even globally, attracting over 15,000 urology experts worldwide every year. At this EAU conference, two kidney cancer-related studies from the team of Dr  Kan Gong of Peking University First Hospital were selected for discussion. The research indicates that the age of first onset is an independent risk factor affecting the prognosis in patients with large fragment deletions of Von Hippel-Lindau (VHL) syndrome. These patients may benefit from tyrosine kinase inhibitor (TKI) treatment. Initial CD4+T cells and memory CD4+T cells may be specific immune cells infiltrating VHL syndrome-related kidney cancer, and their infiltration level is closely related to VHL protein expression and patient prognosis.